Wednesday 22 July 2026

The Pharmaletter

EVOQ Therapeutics

A biotech research company advancing a pipeline of disease-specific immune modulators to treat patients afflicted with autoimmune diseases.

Company Overview

Want to Update your Company's Profile?


Latest EVOQ Therapeutics News

EVOQ Therapeutics pens license deal with Sanofi
16 October 2025
EVOQ Therapeutics and Amgen advance their collaboration
18 January 2023
Gilead links up with EVOQ Therapeutics to advance immunotherapies
3 January 2023
BRIEF—New chief executive at EVOQ Therapeutics
10 January 2023
More EVOQ Therapeutics news >


Today's issue

Samsung Bioepis enters ADC license accord with IntoCell
Biotechnology
Samsung Bioepis enters ADC license accord with IntoCell
22 July 2026
Biosimilars
US House markup of expedited Access to Biosimilars Act welcomed
22 July 2026
Biotechnology
Sanofi publicly reprimanded after UK code breaches over Beyfortus promotion
21 July 2026
Pharmaceutical
Trial miss for Agios Pharma’s tebapivat in sickle cell disease
21 July 2026
Biotechnology
Lonza and Engitix join forces on targeted ADC development
21 July 2026
Pharmaceutical
Novo Nordisk sues Lilly over misleading GLP-1 advertising campaigns
21 July 2026
Biotechnology
EC expands Crysvita approval to infants with rare phosphate disorder
21 July 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze